奥贝胆酸生化应答缺失与原发性胆汁性胆管炎临床事件风险升高相关
该多中心队列研究纳入336例起始奥贝胆酸治疗的PBC患者,随访至2024年6月,评估生化应答与临床事件的关系。12个月生化无应答者临床事件风险显著升高(HR 4.50),肝硬化风险最高(HR 20.24),多变量分析后仍独立相关。
要点
- 奥贝胆酸治疗12个月生化无应答者临床事件风险升高约4.5倍
- 肝硬化患者临床事件风险极高(HR 20.24)
- 48个月内45%患者停用奥贝胆酸,提示需新治疗策略
核心结论
- 奥贝胆酸治疗下生化应答可分层PBC患者临床事件风险,无应答者风险显著升高且多变量分析后仍独立相关。
研究设计与样本
- 多中心回顾性队列研究,收集2017年8月至2019年间在英国、意大利和加拿大大型中心起始奥贝胆酸治疗的PBC患者数据,随访至2024年6月。
- 共纳入336例患者(29%合并肝硬化),随访期间未加用其他PBC治疗。
主要发现
- 48个月内150例(45%)停用奥贝胆酸;12、24、36、48个月随访完成例数分别为230、192、158、150例。
- 12、24、36、48个月生化应答率分别为37%、48%、63%、55%,ALP正常化率分别为7%、14%、25%、19%(与基线比较p<0.01)。
- 4年内64例发生临床事件;12个月生化无应答与临床事件风险升高相关(HR 4.50,95%CI 1.74-20.23)。
- 肝硬化(HR 20.24,95%CI 10.15-40.32)、高胆红素血症(HR 2.55,95%CI 1.71-3.76)、低白蛋白血症(HR 0.92,95%CI 0.90-0.96)、血小板减少(HR 0.99,95%CI 0.98-0.99)亦与临床事件相关。
- 多变量分析中生化无应答(HR 3.29,95%CI 1.72-14.96)和肝硬化(HR 19.67,95%CI 5.09-76.08)的预后价值持续存在。
关键数值与推荐
- 生化无应答采用POISE标准定义。
- 临床事件定义为肝失代偿、转介移植、肝细胞癌或死亡。
临床怎么用
- 对奥贝胆酸治疗12个月未达生化应答的PBC患者应加强监测并考虑调整治疗策略。
- 合并肝硬化、高胆红素血症、低白蛋白血症或血小板减少的患者临床事件风险更高,需重点管理。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Biochemical non-response to ursodeoxycholic acid, as a first-line therapy, is associated with a heightened risk of clinical events in primary biliary cholangitis (PBC). Herein, we determine whether biochemical non-response to second-line therapy in obeticholic acid (OCA) is also predictive of long-term event-free survival. DESIGN: Data were collected from patients who initiated OCA at large, high-volume centres in the UK, Italy, and Canada between August 2017 and 2019, with follow-up continuing until June 2024. Biochemical non-response was defined by POISE criteria. Clinical events were defined as hepatic decompensation, referral for transplantation, hepatocellular carcinoma, or death. RESULTS: Our cohort consisted of 336 patients (29% with cirrhosis), of whom n = 150 (45%) discontinued OCA over 48 months. Over 851 patient-years of OCA use, without the addition of another PBC therapy, n = 230, n = 192, n = 158 and n = 150 patients completed 12, 24, 36 and 48 months follow-up, respectively. Of this cohort, 37%, 48%, 63% and 55% attained biochemical response, with 7%, 14%, 25% and 19% normalising ALP (p < 0.01; all comparisons vs. baseline). Over 4 years, 64 patients experienced a clinical event. Twelve-month biochemical non-response associated with a heightened risk of clinical events (hazard ratio [HR]: 4.50; 95% CI: 1.74-20.23), as did cirrhosis (HR: 20.24, 10.15-40.32), hyperbilirubinaemia (HR: 2.55, 1.71-3.76), hypoalbuminaemia (HR: 0.92, 0.90-0.96) and thrombocytopenia (HR: 0.99, 0.98-0.99). The prognostic utility of biochemical non-response (HR: 3.29, 1.72-14.96) and cirrhosis (HR: 19.67, 5.09-76.08) persisted on multivariable analyses. CONCLUSION: Biochemical response stratifies risk of clinical events in PBC patients under OCA treatment. Whilst response rates increase over time, discontinuation rates underscore the need for newer treatment paradigms.
引用
- Abbas N, Smith R, Lytvyak E, et al. Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis. Aliment Pharmacol Ther. 2025. PMID: 40977287. doi:10.1111/apt.70378
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。